Sharekhan

Alivus Life Sciences Ltd

Wed 30/04/2025,15:54:19 NSE: ALIVUS

₹ 1104.00 13.30 (1.22%)
BUY NOW Buy Alivus Life Sciences Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Alivus Life Sciences Ltd

Wed 30/04/2025,16:1:0

Alivus Life Sciences Ltd

Wed 30/04/2025,15:54:19 | NSE : ALIVUS

₹ 1104.0013.30 (1.22%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1079.10

Previous Close

₹ 1090.70

Volume

136181

Mkt Cap ( Rs. Cr)

₹13528.09

High

₹ 1112.50

Low

₹ 1064.00

52 Week High

₹ 1335.10

52 Week Low

₹ 755.95

Book Value Per Share

₹ 207.16

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Alivus Life Sciences Ltd

Your Vote -

Buy

90.78%

Hold

7.28%

Sell

1.94%

90.78%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

1104.00

445

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

445

Option Chain

Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Apr 2025, 5:26PM Allotment of Equity Shares under the \Employee Stock Options Scheme 2021\

  • Alivus Life Sciences - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    17 Apr 2025, 2:46PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 7:00AM As of March 2025, 74.99% is owned by Indian Promoters and 25.01% by Public. <p align=justify> Institutional holds 11.76% (Insurance Companies 0.22%) a

  • Alivus Life Sciences - General Updates

    3 Apr 2025, 7:30PM Alivus Life Sciences Limited has informed the Exchange about General Updates

  • Alivus Life Sciences - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulatio

    3 Apr 2025, 7:26PM Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Alivus Life Sciences - Acquisition-XBRL

    2 Apr 2025, 5:21PM Alivus Life Sciences Limited has informed the Exchange regarding Acquisition

  • Alivus Life Sciences - Acquisition

    2 Apr 2025, 4:40PM Alivus Life Sciences Limited has informed the Exchange about Acquisition

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Acquisition

    2 Apr 2025, 4:31PM Intimation of Share Purchase cum Subscription Shareholders' Agreement and Power Supply Agreement between Alivus Life Sciences Limited (formerly Glenma

  • Alivus Life Sciences - Alteration Of Capital and Fund Raising-XBRL

    7 Mar 2025, 5:07PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of Securities

  • Alivus Life Sciences - ESOP/ESOS/ESPS

    7 Mar 2025, 5:04PM Alivus Life Sciences Limited has informed the Exchange regarding Allotment of 4190 equity Shares.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    7 Mar 2025, 4:59PM Allotment of Equity Shares under the 'Glenmark Life Sciences Limited - Employee Stock Option Scheme 2021'.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Mar 2025, 2:15PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    3 Mar 2025, 2:11PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting.

  • Alivus Life Sciences - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    27 Feb 2025, 2:27PM ALIVUS LIFE SCIENCES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfe

  • Alivus Life Sciences - Demise

    27 Feb 2025, 2:15PM Alivus Life Sciences Limited has informed the Exchange regarding Demise of Mr. Vijaykumar Ratilal Shah, Independent Director of the company on Februa

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Change in Directorate

    27 Feb 2025, 2:13PM Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Sad demise of Mr. Vijaykumar Ratilal Shah (DIN: 00376570), Independent Director of th

  • Alivus Life Sciences - Action(s) initiated or orders passed

    26 Feb 2025, 2:13PM Alivus Life Sciences Limited has informed the Exchange about Action(s) initiated or orders passed

  • Alivus Life Sciences - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    26 Feb 2025, 2:15PM Please find attached herewith disclosure under Regulation 30 of SEBI (LODR) Regulations 2015.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Feb 2025, 5:17PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Feb 2025, 5:13PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Glenmark Life Science

    11 Jul 2024 , 10:12AM Glenmark Pharmaceuticals' board of directors approved the sale of a 7.84% stake or 96,09,571 equity shares, in Glenmark Life Sciences Limited, as stated in its filing to the exchanges on Wednesday. The stake sale will be done through the stock exchanges via an offer for sale. (Negative)

  • Glenmark Life signs master supply agreement with a Japanese innovator pharma co

    19 Jan 2024 , 11:07AM Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company

  • Glenmark Lifesciences

    31 Jul 2023 , 10:32AM The Nirma Group has emerged as the frontrunner to acquire Glenmark Life Sciences (GLS), an 82.84% subsidiary of Glenmark Pharmaceuticals. Strong positive for Glenmark Lifesciences

  • Glenmark Life Sciences report strong Q1 earnings

    21 Jul 2023 , 1:38PM Glenmark Life Sciences reported an 18% y-o-y rise in revenue to Rs 578.45 Cr in Q1FY24. It was driven by a 13.3% y-o-y increase in Generic API revenue to Rs. 504.2 Cr due to strong growth in regulated markets and steady growth in emerging markets while CDMO business recorded 91.0% growth y-o-y to Rs. 46.4 Cr due to healthy recovery in demand. As gross margins improved 385 bps y-o-y to 57% the gross profits increased 27% y-o-y to Rs. 330.41 Cr. This was driven by lower input costs and improved products mix. As a result, EBITDA increased 32% y-o-y to Rs. 193.16 Cr. while EBITDA margins remained stable y-o-y at 33% in Q1FY24. However, with 193% y-o-y rise in finance costs to Rs. 0.40 Cr the PAT increased at a slower but strong pace of 25% y-o-y to Rs. 135.45 Cr in Q1FY24. However, on a q-o-q basis, revenue and PAT declined at 7% each. Sales declined q-o-q due to high base effect. The management is hopeful of growth in the coming quarters on the back of capacity expansion and product pipeline as well as improved demand environment and supply situation. Positive for the stock.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alivus Life Sciences Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 2332.322 2138.207 2054.312 752.747 401.713
Liabilities 2332.322 2138.207 2054.312 752.747 401.713
Equity 24.505 24.505 24.505 1.96 1.96
Gross Profit 674.246 642.293 616.06 591.074 471.96
Net Profit 470.888 466.961 418.724 351.581 313.098
Cash From Operating Activities 413.515 313.404 597.585 388.113 195.007
NPM(%) 20.62 21.6 19.72 18.64 20.36
Revenue 2283.214 2161.22 2123.214 1885.165 1537.313
Expenses 1608.968 1518.927 1507.154 1294.091 1065.353
ROE(%) 18.54 18.39 16.49 13.85 12.33

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
17 Oct 2023 22.5 1125 0 617.7
24 Mar 2023 21 1050 0 375.3
15 Sep 2022 10.5 525 0 489
22 Nov 2021 10.5 525 0 632.7

Peers

Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 825.75 -1.80 11.65 626.42 1321.50 1.39
Lotus Eye Hospital and Institute Ltd 81.22 -0.17 338.42 2282.60 14.01 0.62
Vaishali Pharma Ltd 13.47 -1.82 449.00 1176.54 2.76 0.00
Astec Lifesciences Ltd 685.90 -1.03 0.00 2152.30 -687.11 0.00

Company Info

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore.

Read More

Parent Organisation

Alivus Life Sciences Ltd.

Founded

23/06/2011

Managing Director

Dr.Yasir Rawjee

NSE Symbol

ALIVUSEQ

FAQ

The current price of Alivus Life Sciences Ltd is ₹ 1104.00.

The 52-week high for Alivus Life Sciences Ltd is ₹ 1112.50 and the 52-week low is ₹ 1064.00.

The market capitalization of Alivus Life Sciences Ltd is currently ₹ 13528.09. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Alivus Life Sciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Alivus Life Sciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alivus Life Sciences Ltd shares.

The CEO of Alivus Life Sciences Ltd is Dr.Yasir Rawjee, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT